読み込み中
GeoVax Labs, Inc. is a biotechnology company in the clinical development phase, focused on creating innovative human vaccines and immunotherapies. The firm targets both infectious diseases and various cancer types, utilizing its proprietary modified vaccinia ankara (MVA) virus-like particle (VLP) vaccine platform. Its product pipeline includes several prophylactic vaccines aimed at preventing illnesses such as COVID-19, human immunodeficiency virus (HIV), Zika virus, malaria, and a range of hemorrhagic fevers like Ebola, Sudan, Marburg, and Lassa. Additionally, GeoVax is developing therapeutic vaccines designed to treat existing conditions, specifically HIV, chronic Hepatitis B infections, and solid tumor cancers. To support its research and development efforts, GeoVax Labs, Inc. has forged partnerships with notable organizations. These collaborators include the National Institute of Allergy and Infectious Diseases (part of the National Institutes of Health), the Centers for Disease Control and Prevention, the U.S. Department of Defense, Emory University, the University of Pittsburgh, and the Burnet Institute. Founded in 1988, GeoVax Labs, Inc. is headquartered in Smyrna, Georgia.
通常取引
$0.2751
−$0.0072 · -2.55%
日中の時刻はETです。市場データは遅延する場合があります。
GeoVax Labs, Inc. is a biotechnology company in the clinical development phase, focused on creating innovative human vaccines and immunotherapies. The firm targets both infectious diseases and various cancer types, utilizing its proprietary modified vaccinia ankara (MVA) virus-like particle (VLP) vaccine platform. Its product pipeline includes several prophylactic vaccines aimed at preventing illnesses such as COVID-19, human immunodeficiency virus (HIV), Zika virus, malaria, and a range of hemorrhagic fevers like Ebola, Sudan, Marburg, and Lassa. Additionally, GeoVax is developing therapeutic vaccines designed to treat existing conditions, specifically HIV, chronic Hepatitis B infections, and solid tumor cancers. To support its research and development efforts, GeoVax Labs, Inc. has forged partnerships with notable organizations. These collaborators include the National Institute of Allergy and Infectious Diseases (part of the National Institutes of Health), the Centers for Disease Control and Prevention, the U.S. Department of Defense, Emory University, the University of Pittsburgh, and the Burnet Institute. Founded in 1988, GeoVax Labs, Inc. is headquartered in Smyrna, Georgia.
日中レンジ
現在 $0.2751
52週レンジ
現在 $0.2751
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
27
割高
センチメント
43
まちまち
リスク
93
極めて高いリスク
モメンタム
17
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
GeoVax Labs, Inc. is a biotechnology company in the clinical development phase, focused on creating innovative human vaccines and immunotherapies. The firm targets both infectious diseases and various cancer types, utilizing its proprietary modified vaccinia ankara (MVA) virus-like particle (VLP) vaccine platform. Its product pipeline includes several prophylactic vaccines aimed at preventing illnesses such as COVID-19, human immunodeficiency virus (HIV), Zika virus, malaria, and a range of hemorrhagic fevers like Ebola, Sudan, Marburg, and Lassa. Additionally, GeoVax is developing therapeutic vaccines designed to treat existing conditions, specifically HIV, chronic Hepatitis B infections, and solid tumor cancers. To support its research and development efforts, GeoVax Labs, Inc. has forged partnerships with notable organizations. These collaborators include the National Institute of Allergy and Infectious Diseases (part of the National Institutes of Health), the Centers for Disease Control and Prevention, the U.S. Department of Defense, Emory University, the University of Pittsburgh, and the Burnet Institute. Founded in 1988, GeoVax Labs, Inc. is headquartered in Smyrna, Georgia.
日中レンジ
現在 $0.2751
52週レンジ
現在 $0.2751
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 248.91万 USD | 395.46万 USD | — | 8.15万 USD | 38.55万 USD |
| 売上原価 | 1812.15万 USD | 9.54万 USD | 2072.08万 USD | 912.35万 USD | 1555.42万 USD |
| 粗利益 | −1563.24万 USD | 385.92万 USD | −2072.08万 USD | −904.2万 USD | −1516.87万 USD |
| 研究開発 | 1812.15万 USD | 2371.36万 USD | 2072.08万 USD | 912.35万 USD | 1555.42万 USD |
| 販売・一般管理 | 600.67万 USD | 538.53万 USD | 594.8万 USD | 498.66万 USD | 357.72万 USD |
| 営業費用 | 600.67万 USD | 2900.35万 USD | 602.22万 USD | 498.66万 USD | 357.72万 USD |
| 受取利息 | 17.43万 USD | 17.34万 USD | 77.62万 USD | 7439 USD | 4736 USD |
| 支払利息 | — | 2.14万 USD | — | — | 1286 USD |
| 減価償却費と償却費 | 6.88万 USD | 9.54万 USD | 7.42万 USD | 5.63万 USD | 3.85万 USD |
| 営業利益 | −2163.9万 USD | −2514.43万 USD | −2674.29万 USD | −1402.86万 USD | −1874.58万 USD |
| 純利益 | −2146.48万 USD | −2499.23万 USD | −2596.68万 USD | −1402.11万 USD | −1857.03万 USD |
会社概要が更新されました 2026年10月13日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$100
上昇余地（36250.42%）| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2026年1月12日 | 1:25 | — | — |
株式分割 | 2024年1月31日 | 1:15 | — | — |
株式分割 | 2020年9月25日 | 1:20 | — | — |
株式分割 | 2020年1月24日 | 1:2,000 | — | — |
株式分割 | 2019年5月2日 | 1:500 | — | — |
株式分割 | 2010年4月28日 | 1:50 | — | — |
発効済み 2026年1月12日
1:25
発効済み 2024年1月31日
1:15
発効済み 2020年9月25日
1:20
発効済み 2020年1月24日
1:2,000
発効済み 2019年5月2日
1:500
発効済み 2010年4月28日
1:50
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
